Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
CROSSMARK LOGO Buy Reprints
PDF

Translate this page into:

Study Letters
87 (
5
); 728-731
doi:
10.25259/IJDVL_796_19
pmid:
34379952

Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis

Department of Dermatology and Venereology, Government Medical College, Kozhikode, Kerala, India
Department of Social and Preventive Medicine Government Medical College, Kozhikode, Kerala, India
Department of Medicine, Government Medical College, Kozhikode, Kerala, India
Corresponding author: Dr. Anza Khader, 5/1986 B, “Maskan” Rajiv Nagar Colony, PO Puthiyara, Kozhikode - 673 004, Kerala, India. anzashaan@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Khader A, Valiaveetil B, Nalini SD, George B, Sasidharanpillai S, Nazeer MM, et al. Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis. Indian J Dermatol Venereol Leprol 2021;87:728-31.

Sir,

Systemic sclerosis is a connective tissue disease affecting the skin, blood vessels and internal organs with significant morbidity and mortality.1 The reduction in skin sclerosis has a beneficial effect on the quality of life and survival of the patients.2,3 Only very few controlled clinical trials have been performed for the treatment of skin sclerosis due to the rarity of the disease and its highly variable course.4

In the present study, we attempted to study the efficacy of low dose cyclophosphamide for a short duration on skin sclerosis in both limited and diffuse types of systemic sclerosis.

We did a single-center open-label interventional study at the department of Dermatology at Government Medical College, Kozhikode, Kerala. We included all diagnosed cases of systemic sclerosis as per the American College of Rheumatology (1980) criteria who attended our outpatient department from the period January 2015 through December 2017. Patients with severe systemic organ involvement [grade IV dyspnoea, cyanosis, severe restrictive lung disease (Forced vital capacity of ≤50% predicted) echocardiogram abnormalities, diffuse infiltrative opacities in chest radiography and patients in renal crisis], those on treatment with prednisolone or other immunosuppressive agents and those who have not completed their family were excluded from the study. The study was approved by the institutional research committee and registered with Clinical Trials Registry-India (CTRI/2015/01/005442 dated 22.1.2015) and all the participants signed written informed consent.

All patients were assessed in detail by a thorough clinical examination and the severity of skin sclerosis was evaluated by the modified Rodnan skin score. Complete hemogram, urine routine, liver and renal function tests, random blood sugar, chest radiography, electrocardiogram, ultrasonogram of abdomen and pelvis, skin biopsy and enzyme immunoassay for antinuclear antibody profile, syphilis and human immunodeficiency virus infections were carried out in all patients. Pulmonary function tests, high-resolution computed tomography of the thorax and esophago-duodenoscopy were also performed in all cases.

All patients were admitted and started on intravenous cyclophosphamide 500 mg in 500 mL 5% dextrose over 2 h in the morning. This was followed by 500 mL of physiologic saline solution along with oral hydration to reduce the risk of bladder toxicity. Monthly pulses for six months were given.All patients received supportive treatment including vasodilators. Modified Rodnan skin score was assessed at the starting and the end of the treatment at six months. Sclerosis was assessed separately at different sites before and after treatment. Patients were closely monitored during and after cyclophosphamide therapy for any adverse effects. The statistical analysis was done using the paired t-test and Wilcoxon signed-rank test. Continuous data were presented as means ± standard deviation for normally distributed variables.

Of the 36 patients enrolled in the study, 34 were women. The mean age of our patients at the time of presentation was 45 ± 9.7 years (range: 29-67 years). The mean duration of disease was 6 years ± 5.1 years (range: 6 months-20 years). Twenty patients (55.5%) were diagnosed to have limited cutaneous type and 16 (44.4%) diffuse cutaneous type. The modified Rodnan skin score of 36 patients ranged from 5 to 33 with a mean value of 19 ± 6.8 [Table 1].

Table 1:: Total MRSS before and after pulse
Patient no: MRSS before MRSS at end of 6 months
1 12 9
2 17 10
3 16 13
4 25 20
5 25 9
6 13 6
7 20 9
8 5 1
9 21 6
10 17 11
11 30 30
12 20 16
13 5 5
14 17 12
15 21 19
16 29 25
17 22
18 11 5
19 33 26
20 29 29
21 16 8
22 18 8
23 12 9
24 15 10
25 21 9
26 17 11
27 20 11
28 15 17
29 8 6
30 28 18
31 27
32 28 22
33 16 6
34 17 18
35 22 11
36 17 10

Out of 36 patients enrolled in the study, two patients failed to complete six months of treatment. The mean modified Rodnan skin score before and after cyclophosphamide therapy at six months was assessed in 34 patients and a significant reduction was noticed from 18.7 ± 6.9 to 12.8 ± 7.2 (P < 0.001). Reduction in the modified Rodnan skin score was noticed from two months of starting the treatment.

There was a significant reduction of modified Rodnan skin score in limited cutaneous systemic sclerosis from 16.5 ± 6 to 10 ± 5.2 (P < 0.001) and in diffuse cutaneous systemic sclerosis from 21.9 ± 7 to 16.8 ± 8 (P = 0.003). Sclerosis at different sites was assessed before and after treatment [Table 2] and we found a significant reduction in mean sclerosis at all sites except on both arms [Table 3]. The right and left forearm and right fingers showed the maximum response.

Table 2:: Number of patients and MRSS scores at different sites before and after treatment in 34 patients
MRSS scores 0 1 2 3
Before After Before After Before After Before After
Face 6 7 13 18 10 8 5 1
Anterior chest 27 30 5 4 2 0 0 0
Anterior abdomen 29 33 5 1 0 0 0 0
Right upper arm 24 27 7 5 3 1 0 1
Left upper arm 24 27 8 5 2 1 0 1
Right forearm 2 11 13 14 18 9 1
Left forearm 3 9 12 16 18 9 1
Right hand dorsum 9 24 12 6 12 2 1 2
Left hand dorsum 11 23 10 7 12 2 1 2
Right fingers 0 1 1 4 6 13 27 16
Left fingers 0 4 6 5 14 25 14
Right thigh 27 31 4 2 2 0 1 1
Left thigh 27 31 3 2 3 0 1 1
Right lower leg 11 20 12 6 9 6 2 2
Left lower leg 11 20 10 6 12 7 1 1
Right foot 6 18 13 7 12 4 3 5
Left foot 6 17 12 8 12 5 4 4
Table 3:: Comparison of mean Modified Rodnan Skin Score at different sites before and after treatment
Site Mean before treatment±SD Mean after treatment±SD P
Face 1.4±0.9 1.1±0.8 0.009
Anterior chest 0.3±0.6 0.1±0.3 0.005
Anterior abdomen 0.1±0.4 0.02±0.2 0.025
Right upper arm 0.4±0.6 0.3±0.7 0.366
Left upper arm 0.3±0.5 0.3±0.7 0.527
Right forearm 1.5±0.7 0.9±0.8 0.000
Left forearm 1.5±0.7 1±0.7 0.000
Right hand dorsum 1.1±0.8 0.5±0.9 0.001
Left hand dorsum 1.1±0.9 0.5±0.9 0.004
Right fingers 2.8±0.5 2.4±0.8 0.000
Left fingers 2.6±0.6 2.3±0.7 0.002
Right thigh 0.3±0.7 0.1±0.6 0.025
Left thigh 0.3±0.8 0.1±0.6 0.034
Right lower leg 1.1±1 0.7±0.9 0.005
Left lower leg 1.1±0.9 0.6±0.9 0.003
Right foot 1.3±0.9 0.9±1.1 0.016
Left foot 1.4±1 0.9±1.1 0.002

SD: Standard deviation

The 34 patients were classified into two groups of low modified Rodnan skin score (<18) and high modified Rodnan skin score (>18). In patients with less than 18 score mean modified Rodnan skin score reduced from 13.7 ± 4.1 to 9.3 ± 4.2 (P < 0.001). In patients with a modified Rodnan skin score of 18 and more, the mean modified Rodnan skin score was reduced from 24.4 ± 4.6 to 16.8 ± 8 (P < 0.001).

Ten out of 13 patients (77%) with dyspnoea and eight out of nine (88.9%) with arthralgia demonstrated improvement of their symptoms. However, there was persistence or exacerbation of gastroesophageal symptoms in a majority (20/22). The incidence of Raynauds phenomenon reduced in 21 out of 26 patients (80.8%), fingertip ulcers subsided in the majority (14/20), recurrence of ulceration on the leg reduced in frequency in six (85.7%) except in one patient and calcinosis in a single patient subsided completely. Though the salt and pepper pigmentation reduced, there was no improvement in diffuse pigmentation and depigmentation in our patients at the end of six months.

Adverse effects included vomiting in two patients, transient elevation of liver enzymes in one patient and temporary amenorrhea in another patient. Cutaneous adverse events included generalized itching in one patient and lichenoid papules in another patient. Gingival hyperplasia was noticed in one of the limited cutaneous systemic sclerosis patients with a positive anti-Scl-70 antibody. Adverse effects were not serious to discontinue treatment.

Our study showed a higher preponderance in women with a female to male ratio of 17: 1 than previous studies.5 The mean age of 45 years in our patients is much higher than in previous studies.5,6

The most common sclerosed site was the fingers followed by the forearm, face and feet. Severe sclerosis of grade three was detected on the fingers in a majority (79.4%) but with less severe involvement on the forearms and dorsa of hands [Table 2].

High dose cyclophosphamide, has been extensively studied for the treatment of systemic sclerosis-related lung disease in three randomized controlled trials but none of the studies evaluated skin scores as the primary target.7,8

A high dose of cyclophosphamide carries a heavy risk of side effects and even death has been reported in one of the previous studies.8 Dexamethasone cyclophosphamide pulse therapy is found to be beneficial but has to be administered for 3 to 4 years.9 Intravenous cyclophosphamide may be better than oral cyclophosphamide to reduce the cumulative dose and is associated with a lower risk of cystitis, and a lower risk of bladder cancer.10

We also attempted to look for site-specific modified Rodnan skin score and compared it with after treatment, when all the sites except both upper arms showed a significant reduction in modified Rodnan skin score. This finding shows that more severely affected distal extremities responded earlier than less severely affected proximal parts.

Dobrota et al. reported that an upper baseline modified Rodnan skin score cutoff value of 18 points is the best indicator of the highest proportion of progressors and the baseline modified Rodnan skin score is the strongest predictor of skin improvement, independent of disease duration.11 de Macedo et al. reported a significant reduction of sclerosis with monthly cyclophosphamide 0.5 to 1.0 g/m2 IV for 18 months but was done on very high modified Rodnan skin score of above 30, the response could not be differentiated from natural regression.4 The mean modified Rodnan skin score of our patients being 19, avoids this possibility of spontaneous regression irrespective of treatment. Our patients with modified Rodnan skin score <18 were separately analyzed and found a significant reduction in skin scores after treatment.

To conclude, we found that a relatively lower dose intravenous cyclophosphamide monthly pulse for a short duration is well tolerated and produces a significant reduction of skin sclerosis in both limited and diffuse cutaneous systemic sclerosis. None of the studies so far has attempted to assess the variation of modified Rodnan skin score in LCSS. Low dose cyclophosphamide pulses are effective in reducing the skin sclerosis in patients with low baseline modified Rodnan skin score or milder skin fibrosis who are likely to progress. Our study is limited by the absence of control and open-label study design.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , , et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327-39.
    [CrossRef] [Google Scholar]
  2. , , , , , , et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2016;68:299-311.
    [CrossRef] [Google Scholar]
  3. , , . Treatment of systemic sclerosis: is there any hope for the future? RMD Open. 2016;2:e000260.
    [CrossRef] [Google Scholar]
  4. , , . Cyclophosphamide: effective in the treatment of severe cutaneous involvement in systemic sclerosis. Bras J Rheumatol. 2009;49:265-75.
    [Google Scholar]
  5. , , , . Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol. 2006;72:416-20.
    [CrossRef] [Google Scholar]
  6. , , . Cross-sectional study on clinical features and histopathology of systemic sclerosis. J Skin Sex Transm Dis. 2019;1:77-83.
    [CrossRef] [Google Scholar]
  7. , , , , , , et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
    [CrossRef] [Google Scholar]
  8. , , , , . High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis. 2008;67:775-81.
    [CrossRef] [Google Scholar]
  9. . Dexamethasome-cyclophosphamide pulse therapy for systemic sclerosis. Indian J Dermatol Venereol Leprol. 2009;75:511.
    [CrossRef] [Google Scholar]
  10. , . Management of Widespread skin thickening in diffuse systemic sclerosis. Curr Treatm Opt Rheumatol. 2016;2:49-60.
    [CrossRef] [Google Scholar]
  11. , , , , , , et al. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: A EUSTAR analysis. Ann Rheum Dis. 2016;75:1743-8.
    [CrossRef] [Google Scholar]

Fulltext Views
1,349

PDF downloads
97
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections